Therapy Areas: Cardiovascular
Akebia Therapeutics' Vafseo (vadadustat) receives Australian Therapeutic Goods Administration approval
27 September 2023 - Akebia Therapeutics, Inc. (Nasdaq: AKBA), a US-based, fully integrated biopharmaceutical company, announced on Tuesday that it has received approval from Australia's Therapeut...
AMO Pharma reveals initial preclinical data from study of investigational therapy AMO-02 for Duchenne muscular dystrophy
20 September 2023 - AMO Pharma Limited, a UK-based privately held clinical-stage specialty biopharmaceutical company, announced on Tuesday its initial preclinical data from a study of the use of the c...
Purpose Life Sciences adds Jeff Kindler and Calum MacRae to strategic advisory board
20 September 2023 - Purpose Life Sciences (PLS), a Canada-based specialty services research partner, announced on Tuesday that it has added Jeff Kindler and Calum MacRae, MD, PhD to the company's...
Caliway Biopharmaceuticals completes enrolment for CBL-0201EFP Phase 2-stage 2 study
19 September 2023 - Caliway Biopharmaceuticals, a Taiwan-based biopharmaceutical company, announced on Monday that it has completed enrolment of subjects in the CBL-0201EFP Phase 2-stage 2 study.The s...
Primary Health Properties plc acquires Irish Enhanced Community Care Facility for EUR29.64m
13 September 2023 - Primary Health Properties plc (LSE: PHP), a UK investor in modern primary healthcare facilities, announced on Wednesday that it has agreed to acquire Ireland's first Enhanced ...
Ondine Biomedical initiates Steriwave evaluation at Mazankowski Alberta Heart Institute in Edmonton, Canada
12 September 2023 - Canadian life sciences firm Ondine Biomedical Inc (LON: OBI) announced on Tuesday that it has commenced an eight-month assessment of its Steriwave nasal photodisinfection technolog...